A
Andrew P. Fosberry
Researcher at GlaxoSmithKline
Publications - 37
Citations - 2199
Andrew P. Fosberry is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Antibacterial agent & DNA. The author has an hindex of 20, co-authored 37 publications receiving 1902 citations.
Papers
More filters
Journal ArticleDOI
Type IIA topoisomerase inhibition by a new class of antibacterial agents.
Benjamin D. Bax,Pan F. Chan,Drake S. Eggleston,Drake S. Eggleston,Andrew P. Fosberry,Daniel R. Gentry,Fabrice Gorrec,Fabrice Gorrec,Ilaria Giordano,Michael M. Hann,Alan Joseph Hennessy,Martin Hibbs,Jianzhong Huang,Emma J. Jones,Jo J. Jones,Kristin K. Brown,Ceri J. Lewis,Earl May,Earl May,Martin R. Saunders,Onkar M. P. Singh,Claus Spitzfaden,Carol Shen,Anthony Shillings,Andrew J. Theobald,Alexandre Wohlkonig,Alexandre Wohlkonig,Neil D. Pearson,Michael N. Gwynn +28 more
TL;DR: This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.
Journal ArticleDOI
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
Alexandre Wohlkonig,Pan F. Chan,Andrew P. Fosberry,Paul Homes,Jianzhong Huang,Michael Kranz,Vaughan R. Leydon,Timothy J. Miles,Neil D. Pearson,Rajika L. Perera,Anthony Shillings,Michael N. Gwynn,Benjamin D. Bax +12 more
TL;DR: A crystal structure of moxifloxacin in complex with Acinetobacter baumannii topoisomerase IV now shows the wedge-shaped quinolone stacking between base pairs at the DNA cleavage site and binding conserved residues in theDNA cleavage domain through chelation of a noncatalytic magnesium ion.
Journal ArticleDOI
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
David J. Payne,William H. Miller,Valerie Berry,John Brosky,Walter J. Burgess,Emile Chen,Walter E. DeWolf,Andrew P. Fosberry,Rebecca Claire Greenwood,Martha S. Head,Dirk A. Heerding,Cheryl A. Janson,Deborah Dee Jaworski,Paul M. Keller,Manley Peter J,Terrance D. Moore,Kenneth A. Newlander,Stewart C. Pearson,Brian J. Polizzi,Xiayang Qiu,Stephen Rittenhouse,Courtney Slater-Radosti,Kevin L. Salyers,Mark A. Seefeld,Martin G. Smyth,Dennis T. Takata,Irene N. Uzinskas,Kalindi Vaidya,Nicola G. Wallis,Scott B. Winram,Catherine C.K. Yuan,William F. Huffman +31 more
TL;DR: Results show that compound 4 is representative of a new, totally synthetic series of antibacterial agents that has the potential to provide novel alternatives for the treatment of S. aureus infections that are resistant to the present armory of antibiotics.
Journal ArticleDOI
Sema7A is a potent monocyte stimulator.
S. Holmes,A.-M. Downs,Andrew P. Fosberry,P. D. Hayes,D. Michalovich,P. Murdoch,K. Moores,J. Fox,K. Deen,G. Pettman,T. Wattam,Ceri J. Lewis +11 more
TL;DR: Although the expression of Sema7A was demonstrated in lymphoid and myeloid cells, no stimulation of cytokine production or proliferation was evident in B or T cells, and Sema 7A is an extremely potent monocyte activator, stimulating chemotaxis at 0.1 pm and inflammatory cytokineproduction and superoxide release at 1–10‰pm.
Journal ArticleDOI
Crystal structure of Staphylococcus aureus tyrosyl-tRNA synthetase in complex with a class of potent and specific inhibitors.
Xiayang Qiu,Cheryl A. Janson,Ward W. Smith,Susan M. Green,Patrick McDevitt,Kyung O. Johanson,Paul S. Carter,Martin Hibbs,Ceri J. Lewis,Alison F Chalker,Andrew P. Fosberry,Judith LaLonde,John M. Berge,Pamela Brown,Catherine S. V. Houge-Frydrych,Richard L. Jarvest +15 more
TL;DR: Crystal structures of this class of potent and specific inhibitors of bacterial tyrosyl‐tRNA synthetases may contribute to the understanding of the catalytic mechanism and provide the structural basis for designing novel antimicrobial agents.